Congruence Therapeutics

Congruence Therapeutics company information, Employees & Contact Information

Explore related pages

Congruence Therapeutics email format Congruence Therapeutics management contacts

Related company profiles:

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.

Company Details

Employees
41
Founded
-
Address
7171 Rue Frederick-Banting, 117,canada
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
https://congruencetx.com
Keywords
biotechnology, computational chemistry, machine learning, protein misfolding.
HQ
Montreal, Quebec
Competitors
Nomic Bio, Sygnature Discovery North America, Paraza Pharma Inc., giiant pharma inc., Modulari-T Bio, Ventus Therapeutics, Cura Therapeutics Inc., Inversago Pharma, Repare Therapeutics, adMare BioInnovations.
Looking for a particular Congruence Therapeutics employee's phone or email?

Congruence Therapeutics Questions

News

Congruence Therapeutics Announces Participation in the 24th Annual Needham Virtual Healthcare Conference - PR Newswire

Congruence Therapeutics Announces Participation in the 24th Annual Needham Virtual Healthcare Conference PR Newswire

Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial - PR Newswire

Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial PR Newswire

Congruence Therapeutics Earns "Fierce 15" Distinction for 2025 - PR Newswire

Congruence Therapeutics Earns "Fierce 15" Distinction for 2025 PR Newswire

Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations - PR Newswire

Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations PR Newswire

Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations at the GBA1 Meeting 2025 - PR Newswire

Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations at the GBA1 Meeting 2025 PR Newswire

Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit - PR Newswire

Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit PR Newswire

Congruence Therapeutics Announces Participation at the Citi Biotech Private Access Day and 2025 Bloom Burton & Co. Healthcare Conferences - PR Newswire

Congruence Therapeutics Announces Participation at the Citi Biotech Private Access Day and 2025 Bloom Burton & Co. Healthcare Conferences PR Newswire

Congruence and Ono Announce Multi-Target Research Collaboration to Generate Small Molecule Correctors for the Treatment of Cancer - PR Newswire

Congruence and Ono Announce Multi-Target Research Collaboration to Generate Small Molecule Correctors for the Treatment of Cancer PR Newswire

Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire

Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer PR Newswire

Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer - PR Newswire

Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer PR Newswire

Companies like Congruence Therapeutics

Ventus Therapeutics logo - Similar company to Congruence Therapeutics

Ventus Therapeutics

88
Nomic Bio logo - Similar company to Congruence Therapeutics

Nomic Bio

94
Inversago Pharma logo - Similar company to Congruence Therapeutics

Inversago Pharma

9
Cura Therapeutics Inc. logo - Similar company to Congruence Therapeutics

Cura Therapeutics Inc.

NA
Repare Therapeutics logo - Similar company to Congruence Therapeutics

Repare Therapeutics

102
Paraza Pharma Inc. logo - Similar company to Congruence Therapeutics

Paraza Pharma Inc.

251
giiant pharma inc. logo - Similar company to Congruence Therapeutics

Giiant Pharma Inc.

3
Modulari-T Bio logo - Similar company to Congruence Therapeutics

Modulari-T Bio

8
adMare BioInnovations logo - Similar company to Congruence Therapeutics

Admare Bioinnovations

71
Sygnature Discovery North America logo - Similar company to Congruence Therapeutics

Sygnature Discovery ...

223

Top Congruence Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant